At the ocular surface, increased levels of IL-17-expressing T cells and decreased levels of FOXP3-expressing Tregs result in corneal barrier disruption and reduced numbers of goblet cells in the conjunctiva (3, 8), and butyrate treatment in mouse SS models can also improve disease. The gene discussed is FOXP3; the disease is synovial sarcoma.